Please provide your email address to receive an email when new articles are posted on . By week 12, itch and pain scores decreased 78.3% and 53.7% in the prurigo nodular and chronic pruritus of ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Nemluvio (nemolizumab-ilto) to treat adults with prurigo nodularis. The approval was supported ...
Demonstrates Long-Term Disease Control In Prurigo Nodularis Up To Three Years - AETOS....(BUSINESS WIRE )--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study inv ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...
Galderma has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis in Australia, ...
The FDA approved the interleukin (IL)-31 monoclonal antibody nemolizumab (Nemluvio) for treating prurigo nodularis, drugmaker Galderma announced on Tuesday. The approval stipulates use in adults with ...
The FDA has granted nemolizumab Priority Review for the treatment of prurigo nodularis. The Food and Drug Administration (FDA) has accepted for review the Biologics License Applications (BLA) for ...
HAMILTON, Bermuda, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa P harmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological ...
San Diego — Nemolizumab, the first-in-class inhibitor of interleukin-31 (IL-31), a neuroimmune cytokine linked to the promotion of pruritis and inflammation, continues to show good efficacy and safety ...
SAN DIEGO -- More than two-thirds of patients with prurigo nodularis obtained long-term relief from itching, skin lesions, and sleep disturbance with the interleukin (IL)-31 antagonist nemolizumab, ...
Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in ...
Nemluvio demonstrated long-term improvements in itch intensity, skin lesions and quality of life The OLYMPIA LTE study was designed to assess the safety and efficacy of Nemluvio in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results